Blockchain Registration Transaction Record

Oncotelic’s Deciparticle Platform Validated for IV Drug Delivery

Oncotelic Therapeutics validates Deciparticle nanoparticle platform with Sapu003 for IV everolimus delivery, published in IJMS. Phase 1b trial ongoing for mTOR-sensitive tumors.

This validation of the Deciparticle platform is important because it addresses a fundamental challenge in drug development: the delivery of hydrophobic, poorly water-soluble compounds. Many promising therapeutics fail due to solubility issues, limiting their effectiveness and patient access. By enabling intravenous delivery of such compounds, this platform could expand the arsenal of treatments for cancer and other diseases, potentially improving outcomes for patients with limited options. The ongoing Phase 1b trial for Sapu003 in mTOR-sensitive tumors represents a tangible step toward clinical application, and the platform's scalability suggests broad future impact across multiple therapeutic areas.